Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Market Cap	2.83B
Revenue (ttm)	767.47M
Net Income (ttm)	140.02M
Shares Out	51.15M
EPS (ttm)	2.74
PE Ratio	20.20
Forward PE	20.25
Dividend	0.94 (1.71%)
Ex-Dividend Date	Jul 14, 2025

Volume	72,514
Average Volume	102,507
Open	54.85
Previous Close	54.75
Day's Range	54.65 - 55.30
52-Week Range	45.52 - 89.50
Beta	0.45
RSI	56.69
Earnings Date	Jul 24, 2025

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,197
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.